Figure 1 | Scientific Reports

Figure 1

From: High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma

Figure 1

A high-throughput drug screen with an EC20 irradiation dose reveals the potential synergistic and antagonistic properties of the drugs. (a) A library of 396 experimental and FDA-approved drugs was tested against five HNSCC cell lines with or without irradiation (top 40 compounds with the highest absolute median values are shown), depicting the relative cell viability quantified as selective drug sensitivity scores (ΔDSS). Red and blue areas, respectively, indicate the potential synergistic and antagonistic combinations with irradiation. The full heatmap appears in Supplementary Figure S1. (b) Average ΔDSS of compounds exhibiting the most promising synergistic and antagonistic properties.

Back to article page